MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.12 per share a year ago. These ...

We recently published 10 Stocks Losing Big. Marker Therapeutics, Inc. (NASDAQ:MRKR) is one of the worst performers of Tuesday. Marker Therapeutics dropped for a second day on Tuesday, slashing 20.63 ...

Marker Therapeutics secures $16.1 million through private placement to advance MT-601 clinical trials for lymphoma treatment. Marker Therapeutics, Inc. announced the completion of a $16.1 million ...

MARKER THERAPEUTICS, INC. (MRKR) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment “Having a rapid available ...

Marker Therapeutics Inc (NASDAQ:MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline ...

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological ...

The presentation will be available for replay starting March 26, 2024 on the Company’s IR website under Events & Presentations. During the conference, Dr. Vera and members of the Marker management ...